CBU
NVAX icon

CIBC Bancorp USA’s Novavax NVAX Stock Holding History

CIBC Bancorp USA’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$101K Sell
10,728
-619
-5% -$5.55K ﹤0.01% 1852
2026
Q1 		$92.4K Buy
+11,347
New +$103K ﹤0.01% 1686
2025
Q3 		$138K Buy
+15,961
New +$124K ﹤0.01% 1320

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

CIBC Bancorp USA's NVAX Position: Q2 2026 in Review

CIBC Bancorp USA reduced its Novavax (NVAX) stake by 5.5% in Q2 2026, selling an estimated $5.55K and leaving 10,728 shares worth $101K. The position accounts for ﹤0.01% of the portfolio, ranked #1852.

CIBC Bancorp USA first reported a position in NVAX in Q3 2025 and has held it in 3 quarters since. The position peaked at $138K in Q3 2025. 266 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • CIBC Bancorp USA held 10,728 shares of Novavax worth $101K as of Q2 2026.
  • CIBC Bancorp USA sold 619 Novavax shares in Q2 2026, an estimated $5.55K.
  • Novavax made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1852 holding.
  • CIBC Bancorp USA first reported a position in Novavax in Q3 2025 and has held it in 3 quarters since.
  • CIBC Bancorp USA's Novavax position peaked at $138K in Q3 2025.
  • 266 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.